- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04650958
SUNDYS: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel-group Trial (SUNDYS)
April 3, 2021 updated by: Bomin Sun, Ruijin Hospital
Subthalamic Nucleus Deep Brain Stimulation in Isolated Generalized or Segmental Dystonia: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel-group Trial
Dystonia is a group of movement disorders characterized by twisting, repetitive movements, or abnormal postures caused by involuntary muscle contractions and is characterized by a young age of onset and a high disability rate.
Early intervention can reduce disability incidence, improve the patient's quality of life, and reduce the burden on families and society.
Multiple international guidelines on dystonia have found deep brain stimulation (DBS) to be a safe and effective treatment for refractory dystonia.
The globus pallidal internus (GPi) is the mostly widely used target for dystonia.
However, there are limitations on the GPi DBS treatment, including slow onset of beneficial effects, poor improvement of axis symptoms, and potential stimulation-related side effects.
Previous studies have described the highly successful use of subthalamic nucleus deep brain stimulation (STN DBS) in patients with refractory dystonia, suggesting that STN DBS is an effective and persisting alternative to pallidal deep brain stimulation.
However, all STN DBS treated cases have been analyzed in open-label uncontrolled cohort studies, leading to limited data with a high level of evidence on the STN DBS in dystonia.
Further, the investigators hypothesized STN has potentially more effectiveness when compared with GPi, and may be more power-saving and quick-acting.
In this study, the investigators will organize a prospective randomized, double-blind, parallel-group, multicenter study comparing active versus sham stimulation in isolated segmental or generalized dystonia to evaluate the effectiveness and safety of STN DBS by measuring the impact on motor status, mental status, quality of life, the rate of response of the patients (the number of patients with ≥30% improvement in the movement score on the Burke-Fahn-Marsden Dystonia Rating Scale) and the rate of adverse events during the trial.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
38
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kejia Hu, MD, PhD
- Phone Number: 18930113801
- Email: dockejiahu@gmail.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Recruiting
- Shanghai Ruijin Hospital
-
Contact:
- Kejia Hu, MD,PhD
- Phone Number: +86 18930113801
- Email: dockejiahu@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must meet criteria for the diagnosis of isolated generalized or segmental dystonia, including idiopathic and inherited dystonia, as defined by the Phenomenology and Classification of Dystonia: A Consensus Update 2013;
- Patients will be ≥ 14 years old;
- The course of disease will be ≥ 3 years;
Patients will have:
- Significant dystonia symptoms;
- Compromised life quality;
- Unsatisfactory response to oral treatment with anticholinergic agents antiepileptic agents, anti-dopamine agents, dopaminergic agents, or muscle relaxants;
- Unsatisfactory response to or contraindication for previous botulinum toxin treatment; and
- Ability to provide written informed consent.
Exclusion Criteria:
- Patients with a diagnosis or probable diagnosis of acquired, compound, and complex dystonia, as defined by the Phenomenology and Classification of Dystonia: A Consensus Update 2013;
- Previous brain surgery for dystonia;
- Patients with cognitive impairment (MMSE score <24) or moderate-severe depressive disorder (BDI>25);
- Patients with marked brain atrophy identified by magnetic resonance imaging (MRI) or computed tomography (CT);
- Patients with other medical or psychiatric comorbidities that could increase the surgical risk or interfere with completion of the trial;
- Patients with increased bleeding risk, or other factors contraindicating neurosurgery or general anesthesia;
- Patients unable to cooperate with the assessments during the follow-up.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: STN DBS stimulation group
In the STN DBS stimulation group, patients will receive a continuous DBS stimulation for 3 months and the first default parameters applied will be monopolar setting (0.5 V under threshold that causes side effects, 135 Hz, 90 µs, at one of the two dorsal contacts).
If the default parameters are found not suitable for an individual patient due to unexpected reasons, an alternative method will be applied (e.g., decreased voltage) to try to maintain full compliance with the scheduled study.
|
Deep brain stimulation (DBS) has been in use to treat patients with movement disorders since 1989, with many thousands of publications showing its effectiveness.
DBS for dystonia received the US FDA mark in 2003 and China FDA mark in 2016.
In this study, the DBS system devices are manufactured and donated by SceneRay (Suzhou, China).
The Stimulator System is implanted by a qualified neurosurgeon and consists of three implantable components: the leads, the extension wires and the neurostimulator.
The DBS programming will start within 1 week after the surgery completed.
|
Sham Comparator: Sham stimulation group
In the sham stimulation group, the programming will also start within 1 week after the surgery, but at each follow-up the DBS system will be turned off after the parameter is adjusted to the threshold that causes side effects without continuous stimulation.
After the 3-month double-blind period the patients can choose to set on the DBS system again and receive regular continuous stimulation treatment.
|
Deep brain stimulation (DBS) has been in use to treat patients with movement disorders since 1989, with many thousands of publications showing its effectiveness.
DBS for dystonia received the US FDA mark in 2003 and China FDA mark in 2016.
In this study, the DBS system devices are manufactured and donated by SceneRay (Suzhou, China).
The Stimulator System is implanted by a qualified neurosurgeon and consists of three implantable components: the leads, the extension wires and the neurostimulator.
The DBS programming will start within 1 week after the surgery completed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change from baseline to 3 months after stimulation of Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) score
Time Frame: Baseline; 3months after stimulation
|
The scale consists of a movement and disability subscale with scores ranging from 0 to 120 and 0 to 30, respectively, higher scores indicating greater impairment.
|
Baseline; 3months after stimulation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Abnormal Involuntary Movement Scale (AIMS)
Time Frame: Baseline; 1 week, 1 month and 3months after stimulation
|
The AIMS is a 12-item clinician-rated scale to assess severity of dyskinesias.
These items are rated on a five-point scale of severity from 0-4.
The scale is rated from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe).
Two of the 12 items refer to dental care.
|
Baseline; 1 week, 1 month and 3months after stimulation
|
36-item Short-Form General Health survey (SF-36)
Time Frame: Baseline; 1 week, 1 month and 3months after stimulation
|
SF-36 is a measure of health-related quality-of-life with a 36-item patient-reported questionnaire that covers eight health domains.
Higher scores indicate a more favorable health state.
|
Baseline; 1 week, 1 month and 3months after stimulation
|
Beck Depression Inventory-II (BDI)
Time Frame: Baseline; 1 week, 1 month and 3months after stimulation
|
BDI contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms.
|
Baseline; 1 week, 1 month and 3months after stimulation
|
Beck Anxiety Inventory (BAI)
Time Frame: Baseline; 1 week, 1 month and 3months after stimulation
|
BAI contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe anxiety symptoms.
|
Baseline; 1 week, 1 month and 3months after stimulation
|
Montreal Cognitive Assessment (MoCA)
Time Frame: Baseline; 3months after stimulation
|
MoCA scores range between 0 and 30.
A score of 26 or over is considered to be normal.
Lower scores indicate more disability.
|
Baseline; 3months after stimulation
|
Cambridge Neuropsychological Test Automated Battery (CANTAB)
Time Frame: Baseline; 3months after stimulation
|
A detailed computerized cognitive battery selected from CANTAB includes: Stockings of Cambridge (SOC) and Spatial working memory (SWM) for executive function; Motor screening task (MOT) and a five-choice series selection task for attention; Paired associates learning (PAL) and Pattern recognition memory (PRM) for memory.
|
Baseline; 3months after stimulation
|
The rate of response
Time Frame: 1 week, 1 month and 3months after stimulation
|
The number of patients with ≥30% improvement in the movement score on the BFMDRS
|
1 week, 1 month and 3months after stimulation
|
The rate of adverse event (AE)
Time Frame: Within 1 week after surgery; 1 week, 1 month and 3months after stimulation
|
Within 1 week after surgery; 1 week, 1 month and 3months after stimulation
|
|
Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS)
Time Frame: 1 week and 1 month after stimulation
|
The scale consists of a movement and disability subscale with scores ranging from 0 to 120 and 0 to 30, respectively, higher scores indicating greater impairment.
|
1 week and 1 month after stimulation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Bomin Sun, Ruijin Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2021
Primary Completion (Anticipated)
December 1, 2021
Study Completion (Anticipated)
January 1, 2022
Study Registration Dates
First Submitted
November 19, 2020
First Submitted That Met QC Criteria
November 25, 2020
First Posted (Actual)
December 3, 2020
Study Record Updates
Last Update Posted (Actual)
April 8, 2021
Last Update Submitted That Met QC Criteria
April 3, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ruijin_SUNDYS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dystonia
-
University of Texas Southwestern Medical CenterMassachusetts General HospitalRecruitingDystonia | Dystonia; Idiopathic | Dystonia, Primary | Dystonia, Secondary | Dystonia, Familial | Dystonia Disorder | Dystonias, Sporadic | Dystonia; Orofacial | Dystonia Lenticularis | Dystonia, Paroxysmal | Dystonia 6 | Dystonia 5 | Dystonia 8 | Dystonia 9 | Dystonia 19 | Dystonia 10 | Dystonia 11 | Dystonia 20 | Dystonia 12 | Dystonia... and other conditionsUnited States
-
Fondation Ophtalmologique Adolphe de RothschildCompletedCervical Dystonia, PrimaryFrance
-
Duke UniversityAmerican Academy of NeurologyNot yet recruitingIsolated Focal Hand DystoniaUnited States
-
University Hospital, MontpellierTerminatedSpasticity | Isolated Cervical Dystonia | Complex DystoniaFrance
-
National Institute of Neurological Disorders and...Active, not recruitingDystonia | Focal Dystonia | Musician's DystoniaUnited States
-
University of FloridaBachmann Strauss Dystonia & Parkinson Foundation, Inc.Completed
-
University Hospital, MontpellierTerminatedTardive Dystonia | Generalized Dystonia | Segmental DystoniaFrance
-
Institut National de la Santé Et de la Recherche...Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
University of Colorado, DenverCompleted
-
National Institute of Neurological Disorders and...Completed
Clinical Trials on Deep brain stimulation
-
Abbott Medical DevicesTerminatedDepressive Disorder, Major | Unipolar DepressionUnited States, Canada, United Kingdom
-
Zhiqi MaoRecruitingParkinson's Disease | Executive Function | Electroencephalogram | Functional Near - Infrared SpectroscopyChina
-
Ali Rezai, MDCompleted
-
University Hospital Inselspital, BerneCompletedMovement Disorder | Urinary Tract DiseaseSwitzerland
-
University of MinnesotaRecruitingParkinson DiseaseUnited States
-
NewronikaTerminatedParkinson DiseaseItaly
-
University of Sao Paulo General HospitalUnknownCerebellar AtaxiaBrazil
-
Butler HospitalMedtronicCompletedObsessive-Compulsive DisorderUnited States
-
Boston Scientific CorporationCompletedParkinson's DiseaseUnited States
-
Qilu Hospital of Shandong UniversityRecruiting